Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
European Journal of Gastroenterology & Hepatology|January 2, 2022
De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalationPepijn W A Thomas, Lisa J T Smits, Maarten Te Groen, et al.
Digestive Diseases and Sciences|July 2, 2017
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel DiseaseLisa J T Smits, Anna Grelack, Lauranne A A P Derikx, et al.
Journal of Crohn'S & Colitis|January 25, 2020
Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease PatientsM E de Jong, L J T Smits, B van Ruijven, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2016
Colorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel DiseaseLauranne A A P Derikx, Lisa J T Smits, Shannon van Vliet, et al.
The Journal of Allergy and Clinical Immunology|December 18, 2017
TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expressionPaulo C M Urbano, Raúl Aguirre-Gamboa, Angel Ashikov, et al.
Inflammatory Bowel Diseases|February 4, 2021
Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel DiseaseShaden Mahmmod, Johannes P D Schultheiss, Ad A van Bodegraven, et al.
Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
Pageof 2